Company Profile
Xenon Stock Price, News & Analysis
- Ticker:
- XENE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
64.55 USD (+0.39%)
Close
Last updated: August 6, 2026
5.06B USD
Market cap
Why the stock is moving
The latest monitored company update is “Xenon Reports Q2 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Ion-Channel Therapeutics
Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling.
Azetukalner
Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing. It is the company's lead late-stage candidate across epilepsy and mood disorders.
Epilepsy Programs
Positive X-TOLE2 results support a planned U.S. submission in focal-onset seizures. Additional Phase 3 studies cover focal-onset seizures outside the United States and primary generalized tonic-clonic seizures.
Depression Programs
The X-NOVA studies evaluate azetukalner in major depressive disorder, while X-CEED extends the program into bipolar depression.
XEN1701
XEN1701 is a NaV1.7 inhibitor in Phase 1 development as a potential non-opioid treatment for acute pain.
XEN1120
XEN1120 is a separate Kv7 modulator in Phase 1 testing for pain, providing a second ion-channel mechanism outside the azetukalner franchise.
Future catalysts
NDA submission for azetukalner in focal-onset seizures in the third quarter of 2026.
Completion of Phase 1 studies of XEN1701 and XEN1120 in the second half of 2026.
Topline Phase 3 X-NOVA2 data for azetukalner in major depressive disorder in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xenon (XENE)?
Xenon (XENE) most recently closed at 64.55 USD, a +0.39% move versus the previous session.
What is the market cap of Xenon (XENE)?
Xenon currently has a market capitalization of 5.06B USD on BioPharmSignal.
What does Xenon do?
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing. It is the company's...
On which exchange is XENE stock listed?
Xenon (XENE) is associated with NASDAQ, Canada, Biopharma.
What is Ion-Channel?
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels.
Which conditions is Xenon targeting with Ion-Channel?
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing. It is the company's...
How does Xenon describe recent progress with Ion-Channel?
NDA submission for azetukalner in focal-onset seizures in the third quarter of 2026. Completion of Phase 1 studies of XEN1701 and XEN1120 in the second half of 2026. Topline Phase 3 X-NOVA2 data for azetukalner in major depressive disorder in the first half of 2027.
What is Therapeutics?
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels.